Bimiralisib has also been shown to have efficacy in combination with BCL2 (B-cell lymphoma 2) inhibitor venetoclax in acute myeloid leukemia (AML) with IDH2, NPM1, and FLT3 mutations in preclinical studies [194]. Here, IDH2 is linked to acute myeloid leukemia.